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Subintimal angioplasty for the treatment
of claudication and critical limb ischemia:
3-year results
Eric C. Scott, MD, Andre Biuckians, MD, MPH, Ryan E. Light, MS, Christopher D. Scibelli, MD,
Timothy P. Milner, MD, George H. Meier III, MD, and Jean M. Panneton, MD, Norfolk, Va
Objective: Subintimal angioplasty (SIA) is an increasingly used method of lower extremity revascularization for patients
with chronic arterial occlusions. To assess the technical feasibility, safety, and 3-year outcomes of patients treated with
SIA, we performed a retrospective review of our early experience.
Methods: Patient information—including demographics, indications, procedures, noninvasive arterial studies, and post-
procedural events—was recorded in a database. Outcomes were determined on an intention-to-treat basis, as well as by
technical success, by using Kaplan-Meier survival analysis. Continuous data were compared by using the Student t test,
and survival curves were compared by log-rank testing.
Results: From December 2002 through December 2003, 104 patients (105 limbs) underwent SIA of 159 occlusive lesions
involving the iliac (n 10), superficial femoral (n 85), popliteal (n 48), or tibial (n 16) arteries. Sixty-six (62.9%)
patients were treated for critical limb ischemia, and 39 patients (37.1%) were treated for disabling claudication. Technical
success was achieved in 91 procedures (86.7%) and resulted in a mean increase in ankle-brachial index of 0.36 0.16. The
mean follow-up was 23.4 months (range, 0-46 months). During this period, 18 patients (17.0%) died, and 15
amputations (14.3%) were performed, 6 of which were performed for patients on whom SIA had been unsuccessful. In
patients undergoing successful SIA, the primary patency was 55%, 43%, and 35% at 12, 24, and 36 months, respectively.
Twenty-one patients underwent a total of 23 percutaneous procedures to maintain or restore patency of the SIA during
the study period. This resulted in secondary patency rates of 71%, 63%, and 51% at 12, 24, and 36 months, respectively.
Multivariate analysis revealed critical limb ischemia to be the only predictor of reduced primary patency. Fifteen patients
with inoperable critical limb ischemia underwent successful SIA. Limb salvage in this group was 54% and 43% at 12 and
36 months, respectively. Limb salvage in operative candidates was 100% and 88% at the same intervals. In patients with
disabling claudication, 94% experienced improvement in symptoms 3 months after the procedure, and 68% of patients
reported sustained improvement at 36 months. In all operative candidates successfully treated with SIA, freedom from
surgical bypass was 83% and 73% at 12 and 36 months, respectively.
Conclusions: SIA for the treatment of lower extremity chronic arterial occlusions is technically feasible, results in minimal
morbidity, and provides satisfactory revascularization without surgical bypass. Secondary patency is comparable to that
of autologous vein bypass and is achieved with a low rate of reintervention. When used as first-line therapy, SIA provides
most patients with limb salvage and freedom from surgical bypass at 3 years. ( J Vasc Surg 2007;46:959-64.)Endovascular therapy is rapidly expanding the number
of treatment options for patients with peripheral vascular
disease. For symptomatic patients with chronic arterial
occlusions, there are now numerous devices and techniques
available to restore blood flow through the native artery.
One of these, subintimal angioplasty (SIA), establishes a
new flow channel within a subintimal plane, circumventing
the occluded true lumen entirely.
SIA enables the treatment of all lengths of arterial
occlusion, including commonly occurring TransAtlantic
Inter-Society Consensus (TASC) II D lesions.1 Our early
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doi:10.1016/j.jvs.2007.06.031experience with the technique began in patients with criti-
cal limb ischemia who were at prohibitive surgical risk or
had no additional bypass options. As technical success and
limb salvage were achieved with consistency, the procedure
was gradually offered tomore fit patients as an alternative to
surgical bypass and, finally, to patients with disabling clau-
dication.
Today, SIA is an accepted technique in the armamen-
tarium of vascular surgeons and interventionalists who treat
patients with chronic arterial occlusions. Although some
long-term data exist from the European centers where SIA
originated,2 most reports detail short-term results. Pub-
lished reports of limb salvage range from 88% to 98% at 12
months,3-6 and primary patency rates at 12 months range
from 50% to 85%.4,6 Secondary patency has been reported
to be as high as 70% at 12 months7 and 74% at 24 months.8
These early results have heightened enthusiasm for the
procedure. However, this enthusiasm remains tempered by
the relative lack of published long-term results. The provi-
sion of sound clinical advice to patients with symptomatic
chronic arterial occlusions choosing between open and
959
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define feasibility, safety, and long-term outcomes, we re-
viewed our early experience with SIA for the treatment of
chronic arterial occlusions in the lower extremity.
MATERIALS AND METHODS
A retrospective review was performed of patients with
critical limb ischemia or disabling claudication who under-
went SIA as primary therapy fromDecember 2002 through
December 2003. Patient demographics, clinic notes, non-
invasive vascular studies, angiographic findings, and oper-
ative reports were reviewed after approval by the institu-
tional review board.
During this period, 105 limbs with arterial occlusion
were treated with SIA in 104 patients. The level of occlu-
sion ranged from the common iliac artery to the tibial
arteries. Most procedures were performed in an angio-
graphic suite, and the remaining procedures were per-
formed in an operating room with nonfixed fluoroscopy if
deep sedation or general anesthesia was required. Retro-
grade common femoral arterial puncture was the preferred
means of angiographic access. After angiography and iden-
tification of an arterial occlusion, patients were systemically
heparinized. In the case of common iliac artery occlusions,
bilateral common femoral access was typically obtained to
enable a “kissing” balloon or stent technique. Infrainguinal
occlusions were typically approached by placement of a
longer sheath over the aortic bifurcation and in proximity
to the occlusion. A soft, hydrophilic 0.035-inch guidewire
in combination with a 4F or 5F angled hydrophilic catheter
(Glidecath; Terumo Medical Corporation, Somerset, NJ)
was most commonly used to perform the subintimal dissec-
tion. Additional catheters that have proven useful in cross-
ing these lesions include the Bernstein catheter (Cook
Medical, Bloomington, Ind) and the Quick-Cross catheter
(Spectranetics Corporation, Colorado Springs, Colo). Pas-
sage of the guidewire along the medial, lateral, anterior, or
posterior border of the arterial wall, guidewire advance-
ment in a helical course across the lesion, and injection of
contrast demonstrating a dissection plane were all indica-
tions of subintimal guidewire location. After confirmation
of catheter re-entry into the true lumen, balloon angio-
plasty was used to dilate the subintimal channel. Stents
were selectively deployed within the channel to further
open regions of suboptimal angioplasty, defined as residual
stenosis greater than 30%. Re-entry devices were not used
because they were not commercially available during this
period. Technical success was defined as the creation of a
subintimal channel bypassing the occlusion, with successful
re-entry into the true lumen and subsequent angioplasty.
After the procedure, patients received clopidogrel for
1 month, and aspirin was continued indefinitely. Patients
were allowed to resume ambulation 6 to 8 hours after the
procedure and were typically discharged home within 24
hours. Clinical follow-up at 1 month, 3 months, and 6 to
12 months after the procedure was routine and included
physical examination and measurement of ankle-brachial
indices. Duplex examination of the subintimal channel andfurther follow-up were obtained at the discretion of the
treating surgeon. Any additional endovascular procedures
to maintain or restore patency of the subintimal channel
were recorded, as were all open surgical revisions, bypasses,
and major amputations performed through November
2006.
Patency of the SIA was defined by at least one of the
following criteria: flow through the vessel demonstrated by
angiography or duplex ultrasonography, maintenance of an
ankle-brachial index greater than 0.10 above the preproce-
dure value,9 or maintenance of a palpable pedal pulse that
was absent before the procedure in an asymptomatic pa-
tient. Resolution of symptoms was not considered an indi-
cator of patency. Any follow-up intervention necessitating
open surgical revision or bypass was reported as such and
was not included in primary assisted or secondary patency.
Symptomatic improvement in patients with critical limb
ischemia was defined as the resolution of rest pain or
healing of ulcers and gangrenous wounds after debride-
ment or minor amputation. Symptomatic improvement in
patients with claudication was defined as improvement in
walking distance, as determined through follow-up visits.
Continuous data are expressed as mean SD and were
compared by using the Student t test. P  .05 was consid-
ered statistically significant. Patency, limb salvage, symp-
tomatic improvement, and freedom from surgical bypass
were determined with Kaplan-Meier survival analysis and
compared by log-rank testing. Patency is presented in terms
of technical success, as well as on an intention-to-treat
basis. The remaining data presented are based on the
technical successes of SIA alone to facilitate the compara-
bility of results between studies at a time when the rate of
technical success remains variable10,11 and alters outcome
data when analyzed on an intention-to-treat basis.
RESULTS
One hundred four patients (105 limbs) underwent SIA
for critical limb ischemia or disabling claudication from
December 2002 through December 2003. Patient demo-
graphics are presented in Table I. The indication for inter-
vention was critical limb ischemia in 66 patients (62.9%)
and disabling claudication in the remaining 39 patients
(37.1%). Twenty-four patients (23.1%) were noted to be at
prohibitive surgical risk in the medical record or were
without surgical bypass options and were considered “non-
operative” in our analysis. Treated arterial occlusions
ranged from the common iliac artery to the tibial vessels.
Patients with occlusion of the femoral or femoropopliteal
segment comprised 81.0% of the study population, and the
remaining patients were treated for iliac, popliteal, or tibial
arterial occlusions (Table II).
SIA was technically successful in 91 (86.7%) of 105
cases. The mean length of iliac artery occlusions was 9.0 
2.1 cm, and the mean length of the infrainguinal arterial
occlusions was 28.2 15.3 cm. Failure to re-enter the true
lumen accounted for all but 1 of the 14 unsuccessful cases.
In these 14 patients, 6 required surgical bypass, and 5
nonoperative patients required major amputation soon
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were no significant differences in technical success based on
the length or location of arterial occlusion.
Stents were used in 22 limbs (21.0%), 7 of which
consisted of primary stenting of common iliac or external
iliac artery subintimal channels. The remaining 15 infrain-
guinal cases involved stent placement for suboptimal angio-
plasty (n 13) or primary stenting of the entry point (n 2).
Stents were limited to the superficial femoral artery in 11 of
these cases, and the above-knee popliteal artery was stented
in 4 cases. There were no significant differences in patency
related to stent use by univariate analysis (Table III).
Periprocedural complications occurred in six patients (5.8%)
and included three guidewire arterial perforations, a retroper-
itoneal hematoma, a femoral artery pseudoaneurysm, and a
distal arterial embolization. Each complication was managed
percutaneously or conservatively. No surgical intervention
was required.
The median follow-up was 29.1 months (range, 0-46
Table I. Patient demographics and risk factors for
peripheral arterial disease
Variable Data
Patients 104
Limbs 105
Age (y)
Mean  SD 67.9  11.8
Range 35.4-90.4
Male 61 (58.7%)
Indication
Critical limb ischemia 66 (62.9%)
Rest pain 19 (18.1%)
Ulceration 39 (37.1%)
Gangrene 8 (7.6%)
Claudication 39 (37.1%)
Risk factors
Coronary artery disease 78 (74.3%)
Hypertension 71 (67.6%)
Tobacco use 61 (58.1%)
Diabetes mellitus 56 (53.3%)
Hyperlipidemia 31 (29.5%)
Previous LE bypass 15 (14.3%)
End-stage renal disease 13 (12.4%)
Nonoperative patients 24 (23.1%)
LE, Lower extremity.
Table II. Distribution of lower extremity arterial
occlusive disease in 105 limbs with 159 segments
occluded
Location n (%)
Iliac 10 (6.3)
Superficial femoral 85 (53.5)
Popliteal 48 (30.2)
Tibial 16 (10.0)
Single-segment occlusion (limbs) 47 (44.8)
Multisegment occlusion (limbs) 58 (55.2)months). Surgical bypass was performed in 22 patients(21.0%) at a mean of 7.1  9.8 months after SIA. Major
amputation (above-knee or below-knee) was required in 15
patients (14.3%) at a mean of 6.1 9.4 months, 5 of whom
were nonoperative patients who had undergone unsuccess-
ful SIA. No amputations were performed in patients with
disabling claudication. The 30-day mortality rate was 0%,
and the 180-day mortality rate was 1.9%. A total of 18
patients (17.0%) died during the study period, 14 of whom
had critical limb ischemia. The mean time to death was
15.1  9.9 months.
In patients successfully treated with SIA, 41 patients
(45%) had periprocedural ankle-brachial indexes measured
before and after the procedure. The mean increase in
ankle-brachial index was 0.36 0.16, from 0.47 0.12 to
0.84  0.18 (P  .0001). Patency determinations were
made on the basis of both duplex ultrasonography and
ankle-brachial index data in 16 patients (17.6%), duplex
ultrasound data alone in 16 patients (17.6%), ankle-
brachial index data alone in 6 patients (6.6%), and the
presence of a palpable distal pulse in the treated limb of 53
patients (58.2%). Primary patency was 55% (SE, 5.9%), 43%
(SE, 6.4%), and 35% (SE, 6.7%) at 12, 24, and 36 months,
respectively (Fig 1). During the follow-up period, 23 addi-
tional endovascular procedures were required in 21 patients
(20.2%) to maintain or restore patency, resulting in a
reintervention rate of 0.21 interventions per patient per
year. This achieved a primary-assisted patency rate of 64%
(SE, 5.6%), 54% (SE, 6.3%), and 46% (SE, 6.8%) at 12, 24,
and 36 months, respectively, and a secondary patency rate
of 71% (SE, 5.3%), 63% (SE, 6.0%), and 51% (SE, 7.4%) at
these intervals (Fig 2). Analyzed according to intention to
treat, primary patency was 48% (SE, 5.4%), 38% (SE, 5.7%),
and 31% (SE, 5.9%) at 12, 24, and 36 months, respectively.
Primary-assisted patency was 55% (SE, 5.3%), 47% (SE,
5.7%), and 40% (SE, 6.1%) at these intervals, and secondary
patency was 62% (SE, 5.1%), 55% (SE, 5.6%), and 44% (SE,
6.6%). Primary and secondary patencies were compared
according to the site of disease and the site of distal true
lumen re-entry, and no significant differences were found
Table III. Univariate analysis of risk factors for loss of
subintimal angioplasty patency
Risk factor HR 95% CI P value
Stent placement 0.53 0.29-1.10 .09
Length of lesion (30
or 30 cm) 0.68 0.32-1.35 .25
Male 0.73 0.35-1.45 .35
Hypertension 0.92 0.48-1.75 .79
Tobacco use 1.00 0.53-1.90 .99
Hyperlipidemia 1.19 0.61-2.31 .61
Coronary artery disease 1.48 0.72-2.87 .31
End-stage renal disease 1.58 0.50-6.15 .38
Diabetes mellitus 2.04 1.18-4.14 .01
Nonoperative candidate 2.43 1.34-10.55 .01
Critical limb ischemia 2.66 1.37-4.56 .003
HR, Hazard ratio; CI, confidence interval.(Table IV). Univariate analysis found diabetes mellitus,
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icant risk factors for reduced primary patency (Table III).
However, in multivariate analysis, only critical limb isch-
emia proved to be a significant risk factor for reduced
primary patency (Table V).
In 55 patients with critical limb ischemia treated with
SIA, limb salvage was attained in 78% (SE, 7.6%) of patients
at 36 months. Fifteen patients who were not operative
candidates and would have otherwise required major am-
putation achieved a limb salvage rate of 54% (SE, 15.6%) at
12 months and 43% (SE, 15.8%) at 36 months. Forty
Fig 1. Primary patency of subintimal angioplasty in patients with
critical limb ischemia or disabling claudication. Patency in techni-
cally successful procedures was 55%, 43%, and 35% at 12, 24, and
36 months, respectively. By intention to treat, patency was 48%,
38%, and 31% at 12, 24, and 36 months, respectively.
Fig 2. Secondary patency of subintimal angioplasty in patients
with critical limb ischemia or disabling claudication. Patency in
technically successful procedures was 71%, 63%, and 51% at 12, 24,
and 36 months, respectively. By intention to treat, patency was
62%, 55%, and 44% at the same intervals. TS, Technical success;
ITT, intention to treat.operative candidates who were treated with SIA instead ofsurgical bypass achieved a limb salvage rate of 100% (SE,
0.0%) and 88% (SE, 8.1%) at 12 and 36 months, respec-
tively.
There were 36 patients treated for disabling claudica-
tion with SIA. Claudication was improved or eliminated in
34 patients (94%) 3 months after the procedure. Sustained
improvement in walking distance was attained in 85% (SE,
6.4%) of patients at 12 months and 68% (SE, 9.4%) of
patients at 36 months. During the follow-up period, five
patients (15%) underwent bypass surgery, and no patient
required amputation.
In total, there were 73 patients with either claudication
or critical limb ischemia who were operative candidates yet
were successfully treated with SIA. Only 16 (22%) of these
patients ultimately underwent surgical bypass. Freedom
from surgical bypass in these patients was 83% (SE, 4.6%),
79% (SE, 5.0%), and 73% (SE, 6.1%) at 12, 24, and 36
months, respectively.
DISCUSSION
New and evolving endovascular techniques are expand-
ing treatment options for patients with peripheral arterial
disease. Although current TASC II guidelines recommend
traditional bypass surgery for patients with TASC C or D
lesions,1 many leading vascular centers now routinely treat
patients with percutaneous methods. This study provides
additional evidence that SIA is safe, results in clinical out-
comes that are comparable to those with open bypass, and
renders surgical revascularization unnecessary in most pa-
tients with chronic arterial occlusions at 3 years.
Patients with peripheral arterial disease present with a
host of significant medical comorbidities that shape not
only their perioperative risk, but also their longevity. More
than 70% percent of patients have significant coronary
artery disease,12 and 15% to 25% have significant cerebro-
vascular disease.13,14 A high prevalence of hypertension,
hyperlipidemia, tobacco use, and diabetes has also been
determined in these patients by epidemiologic surveys.
These risk factors were similarly present in our patient
population. As a result, patients with claudication or
asymptomatic disease have a 35% to 50% risk of stroke,
myocardial infarction, or death at 5 years, and patients with
critical limb ischemia have a 1-year mortality rate of 25%.15
In this context, it should come as no surprise that such
patients, treated with traditional bypass surgery, experience
significant morbidity and mortality. Patients undergoing
aortofemoral bypass procedures develop wound complica-
tions in 4% to 22% of cases and systemic morbidity in 4% to
21% of cases, and the procedure carries an overall 30-day
mortality rate of 4.4%.16 Infrainguinal bypass procedures in
patients with critical limb ischemia result in wound compli-
cations in as many as 24% of patients and are associated with
a perioperative mortality rate of 6.3%.17 The mortality rate
of patients requiring major amputation is approximately
45% at 1 year. Regardless of the operation, these patients
are susceptible to a myriad of complications and experience
significant perioperative mortality.
cant d
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reports. The procedure is performed under light sedation
with local anesthesia, and no incisions are required. In
previous reports of SIA, procedural complications have
occurred in 7% to 17% of cases and include hematoma,
pseudoaneurysm, arterial perforation, arteriovenous fis-
tula, and distal embolization.5-7,18-20 These are com-
monly managed percutaneously without the need for
surgical intervention. Mortality related to the procedure
itself is rare.5-7,18-20
In our series, complications occurred in 5.8% of pa-
tients and resulted in no significant morbidity or mortality.
As reported by others, SIA did not alter the level of surgical
bypass in the patients who ultimately required it.5,7,20 No
patient required surgical intervention to manage peripro-
cedural complications, and there was no mortality at 30
days. Patients were typically observed overnight in the
hospital and discharged the following morning. The lack of
wound-related morbidity, the absence of cardiopulmonary
complications, and the brief hospital stays suggest that SIA
is a safer alternative to surgical revascularization.
In addition to safety, our study demonstrates that SIA is
an effective and durable therapy for lower extremity arterial
occlusion. Our short-term patency results are comparable
to those of previous reports,5-8,21 and our 3-year primary
and secondary patency rates of 35% and 51% provide
needed long-term information about the longevity of SIA,
because there are few reports in the literature. Florenes
et al7 treated 116 patients with SIA for infrainguinal occlu-
sions and demonstrated 3- and 5-year primary-assisted
patency rates of 66% and 64%, respectively. However, only
patients with claudication were included in the study.
Treiman et al6 reported 4-year follow-up on patients with
Table IV. Patency in 91 limbs treated with subintimal ang
disease and the site of true lumen re-entry
Location of re-entry
Primary paten
12 mo
Iliac artery (n  9) 78%  13.9%
SFA (n  33) 53%  9.9%
Popliteal artery (n  35) 54%  10.1%
Tibial arteries (n  14) 46%  15.0%
SFA, Superficial femoral artery.
Log-rank comparison of Kaplan-Meier survival curves failed to show signifi
Table V. Multivariate analysis of risk factors for loss of
primary patency
Risk factor b SE Exp(b) 95% CI P value
Diabetes mellitus 0.43 0.34 1.54 0.79-3.00 .20
Nonoperative candidate 0.66 0.41 1.94 0.88-4.28 .10
Critical limb ischemia 0.82 0.36 2.27 1.12-4.61 .02
b, Coefficient; Exp(b), expected hazard; CI, confidence interval.
Cox proportional-hazards regression.critical limb ischemia and occlusive lesions of the superficialfemoral artery and found primary patency rates of 85% and
64% at 1 and 2 years, respectively. This rapidly diminished
to 18% and 9% in the third and fourth years. This study
examined only 29 patients, however, and stents were de-
ployed throughout the entire subintimal tract in each pa-
tient. Our patients underwent stent placement only as
needed for suboptimal angioplasty, and our results at 3
years are improved. In our experience, follow-up interven-
tions are significantly more difficult in the presence of a
stent, and this knowledge has limited our stent use.
Although the long-term patency of SIA is encouraging,
clinical outcomes seem superior to those that would be
expected on the basis of patency data. This finding has
previously been noted and reflects the ability of SIA to
provide ongoing improvement in claudication, relief from
rest pain, and maintenance of healed wounds even after
restenosis or occlusion of the treated lesion.8 This is likely
the result of additional collateralization of the lower ex-
tremity before SIA failure, as well as continued flow
through proximal arterial side branches that are reperfused
during SIA and remain open when distal portions of the
subintimal channel become stenotic or occlude. In our
series, 68% of patients with claudication reported sustained
improvement in or resolution of symptoms at 3 years.
Similarly, patients with critical limb ischemia experienced
high rates of limb salvage. In operative candidates, limb
salvage was 88% at 3 years, with only 27% of patients
requiring surgical bypass. In nonoperative candidates, pa-
tients who without SIA would have undergone a major
primary amputation, limb salvage was 43% at 3 years. These
clinical findings have not been previously reported in a
similar long-term study and are comparable to or superior
to published reports of surgical bypass.22,23
In our practice, patients with disabling claudication or
critical limb ischemia are routinely offered endovascular
therapy as first-line therapy for chronic arterial occlusions,
and patients invariably choose this option after discussion
of surgical alternatives. After SIA, only 20% of patients with
critical limb ischemia and 15% of patients with claudication
required bypass surgery. Overall, we found that 73% of
patients avoided bypass surgery in the 3 years after SIA. Our
results suggest that SIA is an effective first-line therapy and
that surgical bypass may be unnecessary in most patients
asty according to the location of the distal extent of
Secondary patency
36 mo 12 mo 36 mo
 13.9% 78%  13.9% 78%  13.9%
 11.9% 68%  9.0% 49%  13.6%
 10.6% 84%  6.8% 55%  11.6%
 13.6% 46%  15.0% 34%  15.0%
ifferences between groups. Data are presented as mean  SE.iopl
cy
78%
31%
31%
23%with claudication or critical limb ischemia.
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retrospective design reflects the limited clinical use of pre-
procedural and postprocedural noninvasive testing, which
was less frequent than would be expected in a prospective
trial. As a result, less than half of patients underwent ankle-
brachial index measurement before and after SIA, and
patency was likely underestimated by the lack of objective
testing in patients who were clinically asymptomatic but
without palpable distal pulses. Second, there were a few
patients with isolated iliac, popliteal, or tibial artery occlu-
sions, in comparison to those treated for femoropopliteal
occlusions, thus limiting the applicability of our conclu-
sions to these patients. Finally, clinical end points including
relief from claudication and freedom from surgical bypass
were used to provide additional insight on patient out-
comes, yet each is subjective and susceptible to surgeon
bias.
CONCLUSION
SIA is an appealing alternative to surgical bypass in
patients with symptomatic lower extremity chronic arterial
occlusions. The procedure results in less morbidity and
mortality than traditional bypass surgery and offers compa-
rable clinical results. Percutaneous reintervention to main-
tain or restore patency is required in some patients, but this
is infrequent and substantially lengthens the duration of
patency. When it is used as first-line therapy, most patients
undergoing SIA avoid bypass surgery in the ensuing 3
years.
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